First-Line Treatment of IPEX Syndrome
This protocol addresses IPEX syndrome at first line. The therapeutic goal is complete disease remission, and the approach centres on a curative transplantation strategy. The structured regimen specifies the relevant donor and graft source considerations.
Treatment Approach
The established first-line intervention for IPEX syndrome is allogeneic hematopoietic stem cell transplantation. The full protocol defines the specific donor selection criteria and graft source options that inform clinical decision-making.
Treatment Goals
Disease resolution and complete IPEX syndrome remission. Evidence supports that even partial donor engraftment can be sufficient to achieve full remission.
References
- Currently, the primary therapeutic approach for IPEX syndrome is allogeneic hematopoietic stem cell transplantation (HSCT).
- Allogeneic HSCT is the therapy of choice for IPEX syndrome.
- Cells from either human leukocyte antigen (HLA)-identical siblings or other HLA-matched donors are used for HSCT.
- Patients receive HSCT from cord blood, peripheral blood, or bone marrow.
- Only partial donor chimerism was sufficient for complete IPEX syndrome remission.
- HSCT results in disease resolution with a better quality of life, regardless of age, donor source, or conditioning regimen.
DOI: 10.3390/genes12030323
View source ↗